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abnormally elevated ROS from internal and external sources and 
prevent further damages to mitochondrial and cellular DNA, 
  proteins, and lipids.
Conceivably, neurons are extremely active cells that require  constant 
supply of energy in order for them to carry out highly specialized func-
tions such as regulating the activities of neuronal transmission, recep-
tors, ion channels, transporters and synapses. Thus, mitochondria 
are vital for maintaining the homeostasis and integrity of neuronal 
functions; and mitochondrial damage and dysfunction may lead to 
neurological disorders (Schon and Manfredi, 2003; Chan, 2006).
With exception of a few well characterized familial cases in 
connection with speciﬁ   c gene mutations, Parkinson’s disease 
(PD) is commonly a sporadic, adult-onset, neurological disorder. 
Pathophysiologically, PD is considered as a movement disorder due 
to severe loss of dopamine (DA)-producing cells in the substantia 
nigra pars compacta, although the true origin of PD neurodegen-
eration is still unclear. Nevertheless, recent advances in PD research 
have reached a consensus suggesting that PD is not likely caused by a 
single factor but rather a combination of genetic and environmental 
factors leading to a complex clinical phenotype with underlying 
loss of nigrostriatal DA neurons (Bronstein et al., 2009). Therefore, 
potential success for preventing and treating PD could not be easily 
achieved by a monotherapeutic approach.
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Mitochondrial oxidative stress and dysfunction has been implicated as a possible mechanism 
for the onset and progression of Parkinson-like neurodegeneration. However, long-term 
mitochondrial defects in chronic animal neurodegenerative models have not been demonstrated. 
In this study, we investigated the function of striatal mitochondria 6 weeks after the induction 
of a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson’s 
disease (MPD). Although severe depression of mitochondrial respiration was observed 
immediately after acute administrations of MPTP , we failed to detect a signiﬁ  cant mitochondrial 
inhibition in presence of striatal dopamine (DA) deﬁ  cit 6 weeks after the chronic MPD induction 
in young adult mice. In contrast, when aged mice were chronically treated with MPTP and at 6 
weeks post-treatment, these animals suffered an inhibition of the basal (state 4) and adenosine 
5′-diphosphate-stimulated (state 3) respiration and a fall in adenosine triphosphate level in the 
striatal mitochondria. The aged chronic MPD also brought about a sustained diminution of 
striatal anti-oxidant enzyme levels including that of superoxide dismutases and cytochrome c. 
The mitochondrial deﬁ  cits in the striatum of aged chronic MPD 6 weeks after treatment were 
further correlated with signiﬁ  cant losses of striatal DA, tyrosine hydroxylase, DA uptake 
transporter, and with impaired movement when tested on a challenging beam. Our ﬁ  ndings 
suggest that MPTP may trigger the neurodegenerative process by obstructing the mitochondrial 
function; however, striatal mitochondria in young animals may potentially rejuvenate, whereas 
mitochondrial dysfunction is sustained in the aged chronic MPD. Therefore, the aged chronic 
MPD may serve as a suitable investigative model for further elucidating the integral relationship 
between mitochondrial dysfunction and neurodegenerative disorder, and for assessing the 
therapeutic efﬁ  cacy of mitochondrial protective agents as potential neuroprotective drugs.
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INTRODUCTION
Mitochondria are dynamic organelles that are present in all mam-
malian cells. They are functionally well known for generating 
adenosine triphosphate (ATP) as the source of energy, for seques-
tering excess cytoplasmic Ca++, for producing and disposing of 
reactive superoxide free radicals, and for supporting cell survival 
and preventing cell death (Chan, 2006). Brieﬂ  y, the generation 
of ATP by mitochondria involves oxidative phosphorylation of a 
number of protein complexes within the electron transport chain 
system located in the inner mitochondrial membrane. During 
the process of mitochondrial respiration and ATP production, 
small amounts of molecular oxygen are naturally reduced to form 
reactive oxygen species (ROS) as byproducts, like superoxide free 
radicals. Under healthy conditions, the basal level of ROS pro-
duced within cells is quite low and not harmful. Furthermore, 
a number of mitochondrial anti-oxidant enzymes such as the 
superoxide dismutase (SOD) and cytochrome c can scavenge any 
Abbreviations: ADP, adenosine 5′-diphosphate; ATP, adenosine triphosphate; 
DA, dopamine; DAT, dopamine uptake transporter; DOPAC, 3,4-dihydroxyphe-
nylacetic acid; GAPDH, glyceraldehyde 3 phosphate dehydrogenase; MPD, mouse 
model of Parkinson’s disease; mtDNA, mitochondrial DNA; MPTP, 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine; PD, Parkinson’s disease; ROS, reactive oxygen 
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Many plausible genetic and environmental factors have been 
investigated and linked to both the initiation and progression of 
PD neurodegeneration. Amongst them, neuronal oxidative stress 
and mitochondrial dysfunction have emerged as part reasons for 
instigating the demise of nigrostriatal DA neurons through a series 
of deleterious cellular and molecular events. It is generally believed 
that due to intrinsic genetic and extrinsic environmental factors 
that may cause ROS accumulation and/or fail to eradicate ROS, 
neuronal mitochondria will undergo oxidative damage involving 
depletion of anti-oxidant proteins and activation of a series of cas-
pase-dependent or caspase-independent molecular signaling events 
leading to apoptotic cell death (Dawson and Dawson, 2003; Vila 
and Przedborski, 2003).
On the genetic basis, a number of published reports have asso-
ciated point mutations of mitochondrial DNA (mtDNA) with 
PD neurodegeneration (Wallace, 1997; Gu et al., 2002; Bender 
et al., 2006; Kraytsberg et al., 2006). Furthermore, patients who 
are identiﬁ  ed with mtDNA defects show progressive and disa-
bling Parkinsonian features (Filosto et al., 2007; DiMauro and 
Schon, 2008).
The scientiﬁ  c evidence implicating that exposure to environ-
mental toxic chemicals as a possible contributing factor for caus-
ing cellular oxidative damage and mitochondrial dysfunction in 
association with Parkinson’s disorder has been widely examined 
(Sherer et al., 2002). Self-administration of an illicit designer’s drug, 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) that results 
in human Parkinsonism is an early indication of chemically induced 
toxicity to the nigrostriatal DA neurons (Langston et al., 1983). 
Later, MPTP is found to inhibit oxidative phosphorylation involv-
ing mitochondrial nicotinamide adenine dinucleotide (NADH): 
quinone oxidoreductase (complex-1) of the electron transport 
chain, to increase mitochondrial ROS production, and to deplete 
ATP (Ramsay and Singer, 1986; Ali et al., 1994). Infusion of other 
complex-1 inhibitors, such as rotenone and trichloroethylene to 
rodents results in loss of the nigral DA neurons and produces 
Parkinsonian phenotype suggesting mitochondrial dysfunction 
in PD pathogenesis (Betarbet et al., 2000; Gash et al., 2008). The 
concept of neuronal oxidative stress and mitochondrial complex-1 
inhibition has also been veriﬁ  ed in the substantia nigra pars com-
pacta from human PD (Parker Jr. et al., 1989; Schapira et al., 1990; 
Mann et al., 1992; Floor and Wetzel, 1998).
Genetically modiﬁ  ed animal models are of particular interest as 
they provide evidence that reducing mtDNA expression and dis-
rupting mitochondrial function can lead to respiratory chain break-
down and neuronal death reminiscent of PD phenotype (Ekstrand 
et al., 2007). Over-expression of α-synuclein in cell culture and in 
transgenic mice impairs mitochondrial function and increases their 
vulnerability to MPTP neurotoxicity (Hsu et al., 2000; Song et al., 
2004). On the other hand, α-synuclein knock-out mice are resistant 
to toxicity produced by respiratory chain inhibitors, such as MPTP 
(Dauer et al., 2002; Klivenyi et al., 2006). These ﬁ  ndings strongly 
divulge a role of mitochondrial deﬁ  ciency in α-synucleinopathy 
that is relevant to PD pathogenesis.
As depicted above, most of the ﬁ  ndings that associate mitochon-
drial dysfunction with PD-like DA neuron degeneration have been 
derived from in vitro experiments with isolated mitochondria and 
neuronal cells or from short-term investigations using an acute or 
subacute animal PD model. To further substantiate the functional 
role of mitochondria for the survival of nigrostriatal DA neurons, 
the objective of this research was to examine the long-term integrity 
of striatal mitochondria in a chronic mouse model of Parkinson’s 
disease (MPD).
MATERIALS AND METHODS
ANIMALS
Two different age groups of male, C57BL/6 mice, 6–10 weeks (young 
adult) and 6–10 months (aged retired-breeder), weighing 25–28 
and 35–40 g, respectively were used (Harlan Sprague Dawley, Inc., 
Indianapolis, IN, USA). Mice were housed in single cages with food 
pellets and water available ad libitum. The room was maintained 
at a constant temperature and humidity on a 12-h/12-h light/dark 
cycle. All animal treatments were carried out strictly in accord-
ance to the National Institute of Health Guide for the Care and 
Use of Laboratory Animals (NIH Publications No. 80-23, revised 
1996) and were approved by the Institutional Animal Care and 
Use Committee from the University of Houston. Our experimental 
procedures did not cause signiﬁ  cant animal suffering. A total of 98 
mice were used in the present study.
CHRONIC MOUSE MODEL OF PARKINSON’S DISEASE
To prepare the chronic MPD, mice were injected with a total of 
10 doses of MPTP hydrochloride (25 and 15 mg/kg/injection in 
saline, s.c. for young and aged mice, respectively) in combination 
with an adjuvant, probenecid (250 mg/kg/injection dissolved in 
dimethyl sulfoxide, i.p.) as previously described (Lau et al., 1990; 
Petroske et al., 2001). The 10-dose regimen was administered on 
a 5-week schedule with an interval of 3.5 days between injections. 
MPTP hydrochloride and probenecid were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Experiments were conducted 
6 weeks post-chronic treatment. Safety precautions for the use of 
MPTP during chemical preparation and animal injections were 
taken according to the procedures previously described (Lau et al., 
2005). Control mice were treated with probenecid only. Probenecid 
was used to inhibit the rapid clearance and excretion of MPTP 
and its metabolites from the brain and kidney, and it alone did 
not produce any signiﬁ  cant neurotoxic effect; but in combina-
tion it potentiated the neurotoxicity of MPTP (Lau, 2005; Lau 
et al., 2005; Barber-Singh et al., 2009). For comparison, we also 
included a group of acute MPTP-treated young mice, which were 
injected with two doses of MPTP hydrochloride (25 mg/kg/injec-
tion in saline, s.c.) 2 h apart. Experiments were conducted 2 h 
post-acute treatment.
The chronic MPD used in this study has been well character-
ized. In contrast to the most commonly used acute and subacute 
MPTP mouse models of PD, in which neurological and behavioral 
deﬁ  cits are short-lived and spontaneously reversed soon after the 
treatment, the chronic MPD has long-term neurological deﬁ  cits 
showing many features resembling that of the Parkinson’s syn-
drome lasting for at least 6 months (Lau, 2005). The observed 
features include marked depletion of DA content and terminal 
DA uptake in association with signiﬁ  cant behavioral deﬁ  cit and 
loss of DA cells in the substantia nigra (Lau et al., 1990; Petroske 
et al., 2001; Pothakos et al., 2009). Early neuronal apoptosis and 
delayed appearance of α-synuclein-positive inclusion bodies along Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  3 | 3
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with ultrastructural neuronal damage in the substantia nigra pars 
compacta have also been demonstrated (Meredith et al., 2002; 
Novikova et al., 2006).
ISOLATION OF STRIATAL MITOCHONDRIA
Due to tissue limitation, a crude striatal mitochondrial prepara-
tion that was modiﬁ  ed according to the protocol of Sullivan et al. 
(2000) was used for the mitochondrial respiration assay in this study. 
Brieﬂ  y, striata from each animal were isolated and homogenized with 
a dounce homogenizer in 1 ml of an ice-cold isolation buffer contain-
ing mannitol (215 mM), sucrose (75 mM), bovine serum albumin 
(BSA, 0.1%), EGTA (1 mM), and HEPES (20 mM) at a pH of 7.2. 
All subsequent procedures were carried out at 4°C. The homoge-
nate was centrifuged at 1,300 rpm for 3 min. The supernatant was 
transferred to a new tube and the pellet was suspended in 0.5 ml of 
the isolation buffer and centrifuged again at 1,300 rpm for 3 min. 
The supernatants from both spins were combined and centrifuged 
at 13,000 rpm for 10 min. This latter supernatant was discarded and 
the pellet containing the mitochondrial fraction was suspended in 
0.1 ml of a respiration buffer containing mannitol (215 mM), sucrose 
(75 mM), BSA (0.1%), HEPES (20 mM), MgCl2 (2 mM), and KH2PO4 
(2.5 mM) at a pH of 7.2. The mitochondrial protein concentration was 
determined with the Pierce micro BCA protein assay kit (Rockford, 
IL, USA) measured at an absorbance of 595 nm with a Beckman DU 
640 spectrophotometer (Fullerton, CA, USA).
MITOCHONDRIAL RESPIRATION ASSAY
Since mitochondria are vital organelles responsible for catalyzing 
the oxidation of various substrates through an electron transport 
chain system and for generating ATP to support cell function 
and survival, the respiratory activity of striatal mitochondria was 
measured polarographically with a Clark-type oxygen electrode 
in a sealed, thermo-controlled, and continuously stirred chamber 
(Oxytherm System, Hansatech Instruments, Norfolk, England). 
Crude mitochondrial protein at a concentration of 0.5  mg/ml 
in respiration buffer (see above) was initially equilibrated in the 
electrode chamber at 30°C. The rate of oxygen consumption 
(nmol/min/mg mitochondrial protein) was calculated based on 
the slope of polarographic tracings obtained during state 3 and 
state 4 respiration. All mitochondria preparations had an average 
respiratory control ratio of at least 4.5 when pyruvate (5 mM) and 
malate (2.5 mM) were used as NADH-linked substrates. The state 
3 respiration was initiated by adding adenosine 5′-diphosphate 
(ADP, 150 µM).
MEASUREMENT OF MITOCHONDRIAL ATP
Striatal mitochondrial samples were prepared under conditions 
identical to those of the respiration study. After the completion of 
respiration experiment, the mitochondrial suspension from the 
chamber was recovered and mixed with an equal volume of lysing 
buffer provided in the ATP bioluminescence assay kit (PerkinElmer, 
Waltham, MA, USA). The mitochondrial content of ATP was meas-
ured according to the manufacturer’s instruction. Light emitted 
from luciferase-mediated reaction was captured in a luminometer 
(Wallac Victor II, PerkinElmer) and the sample ATP content was 
extrapolated from a standard curve constructed with a series of 
known ATP concentrations (Tieu et al., 2003).
WESTERN BLOT ANALYSIS
Besides serving as energy generating organelles, mammalian 
  mitochondria also play a pivotal role in regulating the production 
and removal of ROS from internal or external sources. Several key 
anti-oxidant enzymes have been widely studied. Mn SOD (SOD2) 
is located in the mitochondrial matrix where it protects mitochon-
drial targets against the internally generated superoxides. Cu–Zn 
SOD (SOD1) and cytochrome c are capable of removing the super-
oxides generated by external triggers. These anti-oxidant enzymes 
are important for scavenging the elevated ROS and preventing them 
from reaching a toxic level that will cause mitochondrial damage 
and cell death (McCord, 1993; Pereverzev et al., 2003). Therefore, 
loss of anti-oxidant enzymes and release of cytochrome c in associa-
tion with mitochondrial dysfunction in the DA neurons may lead to 
substantial ROS accumulation and cause PD-like neurodegenera-
tion. Thus, we measured the levels of mitochondrial anti-oxidant 
enzymes in conjunction with the striatal DA synthesizing enzyme 
and DA uptake protein in the present study.
For western blot analysis of anti-oxidant protein expression, 
crude striatal mitochondria were prepared according to the pro-
cedure as described above, except that mitochondria were ﬁ  nally 
suspended in Tris–HCl buffer (50 mM, pH 7.4) containing the 
protease inhibitor cocktail purchased from Sigma Chemical Co. 
The mitochondrial protein concentration in each sample was deter-
mined with the Pierce micro BCA protein assay kit and diluted to an 
appropriate ﬁ  nal concentration in a protein solubilization solution 
containing SDS (2%), Tris–HCl (62.5 mM, pH 6.8), glycerol (10%), 
2-mercaptoethanol (5%), bromophenol blue (0.001%). The sample 
was boiled for 5 min and 25 µg of each sample was applied to SDS 
polyacrylamide (12%) gel electrophoresis. The resolved proteins 
were transferred to a PVDF membrane, which was probed with 
polyclonal rabbit anti-Mn-SOD (1:1000, Upstate, Lake Placid, NY, 
USA), polyclonal anti Cu/Zn-SOD (1:1000, Stressgen Bioreagents, 
Victoria, BC, Canada), monoclonal mouse anti-cytochrome c 
(1:750, Chemicon, Temecula, CA, USA), mouse anti-tyrosine 
hydroxylase (anti-TH, 1:1000, Millipore, Temecula, CA, USA), rat 
anti-DA uptake transporter (anti-DAT, 1:1000, Chemicon) and 
monoclonal mouse anti-glyceraldehyde 3 phosphate dehydroge-
nase (anti-GAPDH, 1:3000, Chemicon). Immunoreactivity was 
visualized by a horseradish peroxidase-conjugated goat anti-rabbit 
(1:2000, Chemicon) or goat anti-rat (1:2000, Chemicon) or goat 
anti-mouse IgG (1:1500, Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA) with an enhanced NuGlo chemiluminescent substrate 
(Alpha Diagnostic International Inc., San Antonio, TX, USA). The 
exposure time of the blot on ﬁ  lm was conﬁ  ned to the linear scale 
of detection without exceeding the saturation limit. The intensity 
of the protein bands was measured by densitometry (Fluorochem 
8800, Alpha Innotech Corporation, San Leandro, CA, USA) and 
expressed as a ratio to that of GAPDH to ensure that changes of 
protein level are not simply due to differences in the amount of 
sample loading.
ASSAY FOR STRIATAL DOPAMINE AND 3,4-DIHYDROXYPHENYLACETIC 
ACID CONTENT
The striatal levels of DA and its metabolite, 3,4- dihydroxyphenylacetic 
acid (DOPAC) were determined as previously described (Lau et al., 
2005). Brieﬂ  y, striata from each animal were isolated, weighed and Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  3 | 4
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suspended in 0.5 ml of 0.2 N perchloric acid. Each sample was 
sonicated and centrifuged at 11,000×g for 15 min at 4°C. The 
supernatant was ﬁ  ltered through a 4-mm nylon syringe ﬁ  lter with 
a pore size of 0.45 µm (National Scientiﬁ  c, Rockwood, TN, USA). 
An aliquot of the ﬁ  ltrate was injected into a high performance 
liquid chromatography (HPLC Model 1525, Waters Corporation, 
Milford, MA, USA) equipped with a C18 reverse phase, 3 µ LUNA 
column (100 mm × 2.0 mm, Phenomenex, Torrance, CA, USA). 
The sample was eluted by a mobile phase made of 25 mM NaH2PO4, 
50 mM Na-citrate, 0.03 mM EDTA, 10 mM diethylamine HCl, 
and 2.2 mM sodium octyl sulfate (pH 3.2), 30 ml/l methanol and 
22 ml/l dimethylacetamide at a ﬂ  ow rate of 0.4 ml/min. DA and 
DOPAC peaks were determined by the Coulometric electrochemi-
cal   detector (Model Coulochem III, ESA, Inc., Chelmsford, MA, 
USA) and were calculated by extrapolating the peak area from a 
standard curve (ranging 0.05–1 ng of each chemical standard) con-
structed under the same conditions during each run.
ANIMAL BALANCE PERFORMANCE ON A CHALLENGING BEAM
We monitored the ability of the aged chronic MPD in maintaining 
balance on a challenging beam 6 weeks post-chronic treatment as 
previously described with the young adult mice (Pothakos et al., 
2009). The challenging beam was a 1-m long wooden beam sus-
pended 23 cm above a bench top, which was covered with soft 
pads to protect the mouse in case of a fall. The beam was divided 
in four gradually narrowing sections (25 cm/section) leading to 
the mouse’s home cage. The beam widths of the four sections were 
3.5, 2.5, 1.5, and 0.5 cm in decreasing order. The beam was covered 
with surgical tape that provided sufﬁ  cient surface traction for the 
animals to walk on. There were 1 cm wide ledges hanging 1 cm 
below each side of the beam to encourage the mice to use their 
normal gait strategies even when their limbs slipped. All mice were 
pre-trained for two consecutive days (ﬁ  ve trials per day) with an 
inter-trial interval (ITI) of 10–12 s on traversing the beam. On the 
third day, each mouse was given ﬁ  ve trials (ITI = 10–12 s). The aver-
age number of videotaped limb slips per trial and the time latency 
for returning to the home cage were recorded and compared with 
control mice for statistical analysis. Slips were counted only while 
the mouse was in forward motion.
STATISTICAL ANALYSIS
Statistical comparisons of values between control and treated 
groups were carried out by Student’s t-test. In all cases, a P value 
of <0.05 was considered to be signiﬁ  cant. All data are represented 
as mean ± SEM.
RESULTS
For studying the hypothesis of striatal mitochondrial dysfunction 
in the chronic MPD, we initially used young adult mice at the age 
of 6–10 weeks. We ﬁ  rst replicated the animal model by demonstrat-
ing striatal dopaminergic deﬁ  cit resulting from a 5-week, 10-dose 
treatment with MPTP (25 mg/kg) and probenecid (250 mg/kg) as 
shown in previous studies (Lau et al., 1990; Petroske et al., 2001). 
Thus, 6 weeks after chronic MPD treatment, we detected a sus-
tained 74.9 and 70.9% loss of striatal DA and DOPAC, respec-
tively (Table 1). Acute treatment in young mice with two doses 
of MPTP (25 mg/kg) caused a rapid depletion of 54.1% DA and 
48.3% DOPAC in the striatum 2 h later (Table 1). These results 
indicate that MPTP has an acute effect in depleting the vesicular 
DA stores; and when administered chronically with probenecid, 
MPTP produces a persistent loss of DA in the striatum.
Mitochondrial respiration in the striatum was measured and 
compared between acute and chronic MPD. The basal rates of 
mitochondrial respiration (state 4 respiration) in young adult mice 
were not signiﬁ  cantly different between acute control, acute MPD, 
chronic control, and chronic MPD groups (Table 2). The ADP-
stimulated mitochondrial respiration (state 3 respiration) in young 
acute MPD was markedly reduced when compared with the acute 
control animals (Table 2). To our surprise, the young chronic MPD 
showed no signs of respiratory depression in the striatal mitochon-
dria when compared with that in the chronic control mice (Table 2). 
These data demonstrate that although MPTP has an immediate 
toxic effect on mitochondrial respiration, this defect is not sustained 
6 weeks after the chronic MPTP/probenecid treatment.
We further examined the expression of striatal mitochondrial 
anti-oxidant proteins by western blot analysis. In young acute MPD, 
the levels of Mn SOD, Cu–Zn SOD, and cytochrome c were not signif-
icantly altered in the striatal mitochondria (Figures 1A–C). Similarly, 
the contents of these three proteins 6 weeks after chronic MPTP/
probenecid treatment were not different from either control or acute 
Table 1 | Striatal DA and DOPAC levels in acute and chronic young adult 
(6–10 weeks old) MPD.
Animal group  N  DA (ng/mg tissue)  DOPAC (ng/mg tissue)
Young acute control  5  13.81 ± 1.73  1.43 ± 0.39
Young acute MPD
a 5  6.34  ± 0.86*  0.74 ± 0.27*
Young chronic control  7  12.97 ± 1.33  1.65 ± 0.47
Young chronic MPD
b 7 3.26  ± 0.41**  0.48 ± 0.36**
aThe young acute MPD received two injections of MPTP hydrochloride (25 mg/
kg/dose made in saline, s.c.) 2 h apart. Experiments were conducted 2 h post-
acute treatment. The acute control group received saline only.
bThe young chronic MPD received 10 doses of MPTP hydrochloride (25 mg/kg/
dose in saline, s.c.) in combination with an adjuvant, probenecid (250 mg/kg/
injection dissolved in dimethyl sulfoxide, i.p.). The 10-dose regimen was admini-
stered on a 5-week schedule with an interval of 3.5 days between injections. 
Experiments were conducted 6 weeks post-chronic treatment. The chronic 
control group received probenecid only.
*Signiﬁ  cantly lower than the acute saline control group (P < 0.002).
**Signiﬁ  cantly lower than the chronic probenecid control group (P < 0.0001).
Table 2 | Striatal mitochondrial respiration in acute and chronic young 
adult (6–10 weeks old) MPD
a.
Animal group  N  State 3 respirationb  State 4 respirationb
Young acute control  5  9.62 ± 0.84  2.05 ± 0.39
Young acute MPD  5  4.20 ± 0.64*  1.40 ± 0.15
Young chronic control  6  10.55 ± 0.71  1.65 ± 0.12
Young chronic MPD  5  10.33 ± 0.69  1.80 ± 0.11
aSee legends under Table 1 for animal treatment protocols.
bRate of mitochondrial oxygen consumption in presence (state 3) or absence 
(state 4) of ADP (150 µM). Data are expressed as mean ± SEM in nmol/min/mg 
protein.
*Signiﬁ  cantly lower than the acute saline control group (P < 0.001).Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  3 | 5
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MPD group of young mice (Figures 1A–C). Since the basal levels of 
these proteins in acute saline-treated and chronic  probenecid-treated 
young mice were not statistically different, only the control data from 
chronic probenecid-treated group were presented.
It is possible that the functionality of mitochondria may 
gradually recover in young adult mice after the toxic species of 
MPTP are dissipated from the brain. Before ruling out the pos-
sible association between Parkinson-like neurodegeneration and 
mitochondrial disorder, we were curious to investigate whether 
mitochondrial dysfunction may exist and can be demonstrated in 
aged chronic MPD. Since aged mice are known to be more sensi-
tive to MPTP neurotoxicity (Ricaurte et al., 1987) and also based 
on our own experience that aged mice will not survive the same 
chronic MPTP/probenecid regimen as in young adult mice, there-
fore we treated the aged chronic MPD with a lesser dose of MPTP 
(15 mg/kg) in the present study. Indeed, the 6- to 10-month-old 
mice when treated with 10 doses of MPTP (15 mg/kg, s.c.) and 
probenecid (250 mg/kg, i.p.) over 5 weeks had all survived and they 
displayed 64.6 and 53.3% loss of DA and DOPAC, respectively 6 
weeks after the cessation of treatment (Table 3). Analyses of TH 
and DAT expression in the striatal tissue further revealed that 
there were signiﬁ  cant losses of TH and DAT contents in the aged 
chronic MPD 6 weeks after treatment when compared with that 
of the control animals (Figures 2A,B). These results implicate that 
this modiﬁ  ed chronic MPD treatment in aged mice generates a 
moderate and sustained loss of dopaminergic transmission and 
function in the striatum.
Interestingly, both the basal (state 4) and ADP-stimulated (state 3) 
mitochondrial respiration in the striatum of aged chronic MPD mice 
were signiﬁ  cantly impaired when compared to the chronic control 
animals (Table 4). There was a 50.8 and 41.0% reduction of state 3 
and state 4 respiration, respectively 6 weeks after the chronic MPD 
treatment (Table 4). The mitochondrial ATP level was also decreased 
by 46.9% (Table 4). These data demonstrate that 6 weeks after chronic 
MPTP/probenecid treatment in the aged mice, there is a sustained 
attenuation of mitochondrial respiration and ATP production in the 
striatum. Western blot analyses of anti-oxidant proteins additionally 
showed that the levels of Mn SOD, Cu–Zn SOD, and cytochrome c 
were signiﬁ  cantly reduced in the striatal mitochondria of the aged 
chronic MPD 6 weeks after treatment (Figures 3A–C).
Although the absolute value of the state 3 respiration in aged 
mice (Table 4) appeared to be higher than that in the young mice 
(Table 2), statistical comparison between them was not performed 
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FIGURE 1 | Protein expression of (A) Mn SOD, (B) Cu–Zn SOD, and (C) 
cytochrome c in the striatum of young control, acute MPTP , and 6-week 
post-chronic MPTP/probenecid-treated parkinsonian (MPD) mice. 
Western blot technique and densitometry analysis were used to detect and 
quantify the respective anti-oxidant protein bands and GAPDH. The protein 
contents of Mn SOD, Cu–Zn SOD, and cytochrome c were expressed as a 
ratio to that of GAPDH to ensure that the changes in protein levels were not 
due to sample loading variances. A representative image of western blot 
protein bands was correspondingly shown above each set of bar graph. Each 
data point represents mean ± SEM, N = 6 per group of animals. The levels of 
Mn SOD, Cu–Zn SOD, and cytochrome c in the striatum of young control, 
acute MPTP , and 6-week post-chronic MPD mice were not statistically 
different from each other.
Table 3 | Striatal DA, DOPAC levels in chronic aged (6–10 months old) 
MPD
a.
  Aged chronic   Aged chronic   P value
 control  (N = 5)  MPD (N = 9)
DA (ng/mg tissue)  10.61 ± 0.71  3.76 ± 0.37  <0.0001
DOPAC (ng/mg tissue)  1.67 ± 0.47  0.78 ± 0.16  0.048
aThe aged chronic MPD received 10 doses of MPTP hydrochloride (15 mg/kg/
dose in saline, s.c.) in combination with an adjuvant, probenecid (250 mg/kg/
injection dissolved in dimethyl sulfoxide, i.p.). The 10-dose regimen was admini-
stered on a 5-week schedule with an interval of 3.5 days between injections. 
Experiments were conducted 6 weeks post-chronic treatment. The aged chronic 
control group received probenecid only.Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  3 | 6
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because these two sets of experiments were not performed at the 
same time and under the same conditions. Furthermore, the chronic 
MPD in young and aged animals were treated with a different dose 
of MPTP due to age-related sensitivity. Thus, the aim and design of 
the present study was to directly compare mitochondrial respiration 
between age-matched control and chronic MPD groups under the 
same experimental conditions.
We used the challenging beam in this study to examine the 
animal’s balance and motor coordination skills. Six weeks after 
MPTP/probenecid treatment, the chronic MPD group exhibited a 
signiﬁ  cantly greater number of foot slips on the challenging beam 
than that of the control group (Table 5). In addition, the aged 
chronic MPD mice were more hesitant and took longer time than 
the control animals on the balance beam before returning to the 
home cage (Table 5).
DISCUSSION
There is a large body of in vitro and acute in vivo research ﬁ  nd-
ings suggesting a possible link between mitochondrial dysfunction 
and neurodegenerative disorders. However, very few investigations 
have been conducted and results are inconclusive involving the 
long-term defects of mitochondria in chronic neurodegenerative 
models. In the present study, we investigated mitochondrial respi-
ration and measured mitochondrial anti-oxidant enzyme levels 6 
weeks after the induction of Parkinsonism in a chronic MPD. In 
contrast to our initial hypothesis stating that long-term mitochon-
drial deﬁ  ciency is associated with chronic Parkinsonism, we failed 
to detect a signiﬁ  cant inhibition of either the basal (state 4) or 
ADP-stimulated (state 3) mitochondrial respiration in the striatum 
of young adult chronic MPD mice at 6–10 weeks of age, although 
considerable loss of striatal DA neurotransmitter persisted in these 
animals. Furthermore, we did not ascertain any noticeable change 
in the levels of mitochondrial anti-oxidant enzymes including Mn 
SOD, Cu–Zn SOD, and cytochrome c. Our results may be inter-
preted as either mitochondrial impairment is not an obligatory 
pathophysiological factor for chronic neurodegenerative process 
or MPTP may instigate oxidative stress and inﬂ  ammation to the 
mitochondria in other types of striatal cells in addition to the DA 
neurons; consequently, striatal mitochondria in the non-DA cells 
plus or minus DA neurons in young animals may have the capabil-
ity to rejuvenate their functionality over time when the neurotoxin 
clears away from the brain. The latter possibility on cell speciﬁ  city 
was not tested in the present study due to tissue limitation.
For comparison, we conﬁ  rmed that acute injections of MPTP 
caused an immediate depletion of striatal DA and simultaneously 
suppressed the state 3 mitochondrial respiration. These observa-
tions are in line with the premise that neurodegeneration may be 
provoked by MPTP causing accumulation of excitotoxic mediators, 
production of oxidative free radicals, disruption of Ca++ home-
ostasis, and ATP depletion in association with an inhibition of 
the neuronal mitochondrial complex I component of the electron 
transport chain (Przedborski and Jackson-Lewis, 1998; Blum et al., 
2001). However, whether neurodegeneration follows a progressive 
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FIGURE 2 | Western blot analysis of (A) TH and (B) DAT expression in the 
striatum of aged chronic probenecid control and aged chronic MPD mice. 
A representative image of western blot protein bands was correspondingly shown 
above each set of bar graph. The protein contents of TH and DAT were expressed 
as a ratio to that of GAPDH and each data point represents mean ± SEM (N = 5 for 
chronic control and N = 8 for chronic MPD). Western blots revealed that there were 
signiﬁ  cant reductions of TH and DAT content in the striatum of aged MPD 6 weeks 
after chronic treatment when compared with that of the control mice (*P < 0.001).
Table 4 | Mitochondrial respiration and ATP levels in the striatum of 
chronic aged (6–10 months old) MPD
a.
  Aged chronic   Aged chronic   P value
 control  (N = 6)  MPD (N = 5)
State 3 respiration   16.31 ± 0.39  8.03 ± 0.43  <0.0001
(nmol/min/mg protein)
State 4 respiration   2.61 ± 0.22  1.54 ± 0.11  0.005
(nmol/min/mg protein)
ATP (nM/mg protein)  12.85 ± 0.75  6.82 ± 0.64  0.0002
aSee legends under Table 3 for animal treatment protocols.Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  3 | 7
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course or not would depend on how rapid and how long the brain 
is exposed to neurotoxic chemicals. Indeed, the DA depleting effect 
of MPTP, when it is administered acutely or subacutely in mice, 
tends to be short-lived and reversible (Lau, 2005). In addition, as 
expected and shown in our results, we did not detect an immediate 
action of MPTP on turning over the anti-oxidant enzyme levels of 
SODs and cytochrome c in acutely treated young mice. We did not 
further carry out the long-term investigation of acute MPTP on 
mitochondrial respiration, SODs and cytochrome c contents. We do 
not anticipate that acute MPTP will cause any sustained mitochon-
drial changes, because even chronically repeated administration of 
MPTP/probenecid in young mice did not generate any signiﬁ  cant 
alterations in mitochondrial respiration and anti-oxidant enzyme 
levels at 6 weeks after treatment.
To address the possibility that striatal mitochondria in young ani-
mals may have the potential for functional recovery over time when 
the neurotoxin is eliminated from the brain, we decided to examine 
the long-term neuronal and mitochondrial toxic effects of chronic 
MPTP/probenecid in an aged group of animals (6–10 months old). 
Resembling the observations from young adult animals, even with 
a reduced dose of MPTP (15 mg/kg/injection), the aged chronic 
MPD acquired signiﬁ  cant losses of striatal DA, DOPAC, TH and 
DAT to a moderate level at 6 weeks post-treatment. In contrast to 
the young animals, the aged chronic MPD consistently suffered an 
inhibition of the basal and ADP-stimulated respiration and a fall 
in ATP production in the striatal mitochondria. Chronic MPTP/
probenecid treatment in aged mice also brought about a sustained 
diminution of striatal anti-oxidant enzyme levels including that 
of Mn SOD, Cu–Zn SOD, and cytochrome c. The striatal neuro-
chemical and mitochondrial deﬁ  cits in aged chronic MPD 6 weeks 
after treatment were further supported by behavioral observations 
showing that these animals made more foot-slip errors and it took 
twice as long for them to complete the challenging beam test.
It should be emphasized that a close correlation between neu-
ronal, mitochondrial, and behavioral deﬁ  cits 6 weeks after chronic 
Parkinsonism in the aged animals would suggest an important 
role of mitochondrial function in maintaining neuronal plastic-
ity. However, such a positive correlation alone is not sufﬁ  cient for 
establishing a cause-and-effect relationship between mitochondrial 
disorder and Parkinson-like neurodegeneration. Furthermore, our 
failure for demonstrating long-term mitochondrial deﬁ  ciency in 
the young chronic MPD would not dispute the possibility that neu-
rotoxins like MPTP can cause mitochondrial oxidative dysfunction 
and trigger the neurodegenerative process, but the mitochondria 
may potentially revive from the initial insult in young animals. 
This is well demonstrated in the present study that mitochondrial 
functions are fully intact whereas neuronal functions are severely 
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FIGURE 3 | Protein expression of (A) Mn SOD, (B) Cu–Zn SOD, and 
(C) cytochrome c in the striatum of aged chronic probenecid control and 
aged chronic MPD mice. A representative image of western blot protein 
bands was correspondingly shown above each set of bar graph. The protein 
contents of Mn SOD, Cu–Zn SOD, and cytochrome c were expressed as a 
ratio to that of GAPDH and each data point represents mean ± SEM, N = 6 per 
group of animals. Statistical analyses revealed that the levels of Mn SOD, 
Cu–Zn SOD, and cytochrome c in the striatum of aged chronic MPD 6 weeks 
after chronic treatment were signiﬁ  cantly lower than that of chronic control 
animals (*P < 0.05).
Table 5 | Challenging beam performance of chronic aged (6–10 months 
old) MPD
a.
  Aged chronic   Aged chronic   P value
 control  (N = 25)  MPD (N = 31)
Average number of slips  5.1 ± 0.3  6.8 ± 0.5  0.008
Average latency (sec)  7 .8 ± 0.9  13.5 ± 1.3  0.001
aSee legends under Table 3 for animal treatment protocols.Frontiers in Aging Neuroscience  www.frontiersin.org  December  2009 | Volume  1 | Article  3 | 8
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mutations accumulate in aging 
human tissues. Mutat. Res. 275, 
157–167.
Barber-Singh, J., Seo, B. B., Nakamaru-
Ogiso, E., Lau, Y. S., Matsuno-Yagi, A., 
and Yagi, T. (2009). Neuroprotective 
effect of long-term NDI1 gene expres-
sion in a chronic mouse model of 
Parkinson disorder. Rejuvenation Res. 
12, 259–267.
Beal, M. F. (2005). Mitochondria take 
center stage in aging and neurodegen-
eration. Ann. Neurol. 58, 495–505.
Bender, A., Krishnan, K. J., Morris, C. 
M., Taylor, G. A., Reeve, A. K., Perry, 
R. H., Jaros, E., Hersheson, J. S., Betts, 
J., Klopstock, T., Taylor, R. W., and 
impaired 6 weeks after chronic MPD treatment in young mice. The 
main signiﬁ  cance of this investigation is the ﬁ  nding of coexisted 
phenotype between neurodegenerative and mitochondrial defects 
in the aged chronic MPD. This will provide an appropriate model 
for continuously establishing whether these two disorders are 
cause-and-effect related and for using these altered neurobiologi-
cal indicators as biomarkers for potential neuroprotective targets in 
preclinical tests. One of the approaches that we currently undertake 
using this model in our laboratory is to elucidate whether long-term 
physical exercise could simultaneously offer mitochondrial as well 
as neuronal protection in the neostriatum.
The topic on deterioration of mitochondrial functions asso-
ciated with normal aging or correlated with age-related diseases 
has been widely reviewed (Calabrese et al., 2001; Bertoni-Freddari 
et al., 2004; Crompton, 2004; Martin, 2006; Arduino et al., 2009; 
Swerdlow, 2009). In the laboratory, neurons isolated from the brains 
of aged rats show deﬁ  ciency in cytochrome c and inner mitochon-
drial membrane-associated cardiolipin levels that would preempt 
normal mitochondrial respiration and oxidative phosphorylation 
(Jones and Brewer, 2009). A single dose of MPTP (40 mg/kg) does 
not acutely generate ROS in young mice, but signiﬁ  cantly releases 
ROS in old mice (Ali et al., 1994). Moreover, although attempts have 
been made to link mutations of mtDNA directly to normal aging 
or age-related disease states, it has not been conﬁ  rmed that mtDNA 
mutations are either the primary cause or the result of aging or 
disease process (Arnheim and Cortopassi, 1992; Wallace, 1997; 
Kang and Hamasaki, 2005; Reeve et al., 2008). For translational 
consideration, one can envision that the capacity of mitochondria 
for carrying out oxidative respiration and generating ATP and for 
coping with acute oxidative insult in the neuron of a 20-year-old 
would be much greater than that of a 70-year-old individual. In 
other words, the mitochondria and neurons of an aged person 
would be more subject to irreparable injuries following chronic 
exposure to endogenous or exogenous toxic chemical species. As 
implicated in the present study, our results are in agreement with 
the notion that the anti-oxidant capacity and the recovery potential 
for mitochondria and neurons post-injury are expected to decline 
with increase in age (Beal, 2005).
It is reasonable to presume that normal physiological release of 
ROS from mitochondria is insigniﬁ  cantly low and is unlikely to 
cause neuronal death. Therefore, intentional reduction of endog-
enously produced ROS below its basal physiological level would 
not be considered health beneﬁ  cial. However, if chronic exposure 
to neurotoxic chemicals like MPTP results in lasting depletion of 
anti-oxidant enzymes such as SODs and cytochrome c in the aged 
subject, as demonstrated in the current study, the loss of mitochon-
drial anti-oxidant protection can certainly exacerbate neurotoxicity 
and cell death initiated by the elevated ROS. Thus, developing new 
approaches for protecting the capacity of mitochondrial defense 
system, for eradicating the elevated ROS level, and for restoring the 
mitochondrial respiratory functions would be important strategies 
for preventing and treating progressive cell death under oxidative 
stress conditions.
CONCLUSION
In summary, the present study examined the role of striatal mito-
chondrial function in the chronic MPD. Although we conﬁ  rmed 
that MPTP acutely suppressed mitochondrial respiration, it did 
not cause a long-lasting inhibitory effect or deplete anti-oxi-
dant enzymes in the young chronic MPD. These data suggest 
that MPTP may initiate neurodegenerative process by blocking 
mitochondrial respiration, yet the mitochondria in the striatum 
of young animals have the potential for recovery. However, we 
demonstrated that aged mice were more vulnerable to chronic 
MPTP toxicity. Long-term inhibition of mitochondrial respira-
tion, depletion of anti-oxidant enzymes and ATP were displayed 
in aged mice coincided with marked loss of striatal DA neuronal 
functions and impaired motor response. These results indicate 
that aged chronic MPD may serve as a suitable investigative 
model for further elucidating the integral relationship between 
mitochondrial dysfunction and neurodegenerative disorder, and 
for assessing the therapeutic efﬁ  cacy of mitochondrial protective 
agents as potential neuroprotective drugs.
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